# Valneva Austria GmbH clinical trials: 44 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 44 trials with Valneva Austria GmbH as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Valneva Austria GmbH: 44 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/valneva-austria-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 44
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 44, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 17, 2026 | NCT07414524 | VLA1553-403 Pregnancy Surveillance Study | Valneva Austria GmbH | Observational | Enrolling by invitation | Chikungunya Virus Infection | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414524) |
| January 16, 2026 | NCT07347002 | Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil | Valneva Austria GmbH | Observational | Enrolling by invitation | Chikungunya Virus Infection | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07347002) |
| November 28, 2025 | NCT07254702 | Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination... | Valneva Austria GmbH | Observational | Active not recruiting | Chikungunya Virus Infection | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254702) |
| September 9, 2025 | NCT07163845 | Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553... | Valneva Austria GmbH | Observational | Active not recruiting | Chikungunya Virus Infection | 5,354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07163845) |
| August 20, 2025 | NCT07133178 | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children | Valneva Austria GmbH | Phase 3 | Withdrawn | Chikungunya Virus Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133178) |
| March 28, 2024 | NCT06334393 | Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy... | Valneva Austria GmbH | Phase 1 | Completed | Zika, Zika Virus Infection | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06334393) |
| October 30, 2023 | NCT06106581 | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years | Valneva Austria GmbH | Phase 2 | Completed | Chikungunya Virus Infection | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06106581) |
| September 8, 2023 | NCT06028841 | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) | Valneva Austria GmbH | Phase 3 | Withdrawn | Chikungunya Virus Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06028841) |
| May 6, 2022 | NCT05364242 | VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection | Valneva Austria GmbH | Phase 2/3 | Completed | SARS-CoV-2 Infection | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05364242) |
| March 28, 2022 | NCT05298644 | COVID-19 Paediatric VLA2001-321 Study | Valneva Austria GmbH | Phase 2/3 | Withdrawn | SARS-CoV-2 Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05298644) |
| July 9, 2021 | NCT04956224 | Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years | Valneva Austria GmbH | Phase 3 | Completed | SARS-CoV-2 Virus Infection | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04956224) |
| April 29, 2021 | NCT04864561 | COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 | Valneva Austria GmbH | Phase 3 | Completed | SARS-CoV-2 Virus Infection | 4,034 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04864561) |
| April 9, 2021 | NCT04838444 | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) | Valneva Austria GmbH | Phase 3 | Active not recruiting | Chikungunya Virus Infection | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04838444) |
| March 8, 2021 | NCT04786444 | Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults | Valneva Austria GmbH | Phase 3 | Completed | Chikungunya Virus Infection | 409 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04786444) |
| December 17, 2020 | NCT04671017 | Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine... | Valneva Austria GmbH | Phase 1/2 | Completed | SARS-CoV-2 Virus Infection | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04671017) |
| September 14, 2020 | NCT04546724 | Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults | Valneva Austria GmbH | Phase 3 | Completed | Chikungunya Virus Infection | 4,128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04546724) |
| July 3, 2018 | NCT03576183 | Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 | Valneva Austria GmbH | Phase 2 | Completed | Enterotoxigenic Escherichia Coli Infection, Diarrhea | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03576183) |
| February 7, 2018 | NCT03425149 | Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in... | Valneva Austria GmbH | Phase 1 | Completed | Zika Virus, Zika Virus Infection | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03425149) |
| December 26, 2017 | NCT03382964 | Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers | Valneva Austria GmbH | Phase 1 | Completed | Chikungunya | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03382964) |
| December 15, 2014 | NCT02316470 | Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and... | Valneva Austria GmbH | Phase 2 | Completed | Clostridium Difficile | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02316470) |
| March 26, 2012 | NCT01563263 | Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 | Valneva Austria GmbH | Phase 2/3 | Completed | Pseudomonas Aeruginosa Infection | 803 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01563263) |
| March 21, 2012 | NCT01559831 | Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination | Valneva Austria GmbH | Phase 1 | Withdrawn | Japanese Encephalitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01559831) |
| April 14, 2011 | NCT01335412 | Safety Surveillance After Immunization With IXIARO | Valneva Austria GmbH | Observational | Completed | Japanese Encephalitis | 20,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01335412) |
| February 15, 2011 | NCT01296386 | An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 | Valneva Austria GmbH | Phase 1 | Completed | Clostridium Difficile Infection | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01296386) |
| February 15, 2011 | NCT01296360 | Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country | Valneva Austria GmbH | Phase 3 | Completed | Japanese Encephalitis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01296360) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 3 |
| Phase 3 | 20 |
| Phase 4 | 1 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Withdrawn | 4 |
| Active not recruiting | 3 |
| Enrolling by invitation | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Encephalitis, Japanese | 15 |
| Chikungunya Fever | 11 |
| COVID-19 | 5 |
| Hepatitis C, Chronic | 2 |
| Zika Virus Infection | 2 |
| Encephalitis | 2 |
| Pseudomonas Infections | 2 |
| Pneumococcal Infections | 1 |
| Diarrhea | 1 |
| Clostridium Infections | 1 |
| Pneumonia, Ventilator-Associated | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Truck rental companies in the United States](https://specstream.ai/data/businesses/truck-rental-companies/united-states)
- [Cambodian restaurants in the United States](https://specstream.ai/data/businesses/cambodian-restaurants/united-states)
- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
- [Packing supply stores in the United States](https://specstream.ai/data/businesses/packing-supply-stores/united-states)
